TY - JOUR
T1 - Kohlschütter-Tönz syndrome
T2 - Case report with novel feature and detailed review of features associated with ROGDI variants
AU - Liepina, Lelde
AU - Kalnina, Marija Luize
AU - Micule, Ieva
AU - Gailite, Linda
AU - Rots, Dmitrijs
AU - Kalnina, Julija
AU - Strautmanis, Jurgis
AU - Celmina, Marta
N1 - Funding Information:
We thank the patient's family for consenting to this publication and Dr. Liene Zamure-Damberga (dentist, Institute of Stomatology, Riga Stradins University, Riga, Latvia) for the input in the section on AI, as well as helping us to classify and describe the dental morphology of our patient.
Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2022
Y1 - 2022
N2 - Kohlschütter-Tönz syndrome (KTS) is a rare, autosomal recessive syndrome characterized by a triad of epilepsy, amelogenesis imperfecta and severe global developmental delay. It was first described in a Swiss family in 1974 by Alfried Kohlschütter and Otmar Tönz. It is caused by pathogenic variants in the ROGDI gene. To the best of our knowledge, there are currently 43 patients with a confirmed ROGDI gene pathogenic variant reported. Here, we review in detail the clinical manifestations of KTS, provide an overview of all reported genetically confirmed patients, and document an additional case of KTS-a 6-year-old Latvian girl-with a confirmed ROGDI gene pathogenic variant. In contrast to previous reports, we detected idiopathic bilateral nephrocalcinosis in this newly identified KTS patient. Perampanel proved an effective treatment for our patient with prolonged super-refractory status epilepticus. In order to better characterize this rare syndrome and its clinical course, it is important to report any additional symptoms and also the effectiveness of used therapies. Future research should focus on elucidating the mechanisms by which the absence/insufficiency of ROGDI-encoded protein causes the clinical manifestations of KTS. This knowledge could shape possible ways of influencing the disease's natural history with more effective therapies.
AB - Kohlschütter-Tönz syndrome (KTS) is a rare, autosomal recessive syndrome characterized by a triad of epilepsy, amelogenesis imperfecta and severe global developmental delay. It was first described in a Swiss family in 1974 by Alfried Kohlschütter and Otmar Tönz. It is caused by pathogenic variants in the ROGDI gene. To the best of our knowledge, there are currently 43 patients with a confirmed ROGDI gene pathogenic variant reported. Here, we review in detail the clinical manifestations of KTS, provide an overview of all reported genetically confirmed patients, and document an additional case of KTS-a 6-year-old Latvian girl-with a confirmed ROGDI gene pathogenic variant. In contrast to previous reports, we detected idiopathic bilateral nephrocalcinosis in this newly identified KTS patient. Perampanel proved an effective treatment for our patient with prolonged super-refractory status epilepticus. In order to better characterize this rare syndrome and its clinical course, it is important to report any additional symptoms and also the effectiveness of used therapies. Future research should focus on elucidating the mechanisms by which the absence/insufficiency of ROGDI-encoded protein causes the clinical manifestations of KTS. This knowledge could shape possible ways of influencing the disease's natural history with more effective therapies.
KW - Kohlschütter–Tönz syndrome
KW - amelogenesis imperfecta
KW - ectodermal dysplasia syndrome
KW - nephrocalcinosis
KW - super-refractory status epilepticus
UR - http://www.scopus.com/inward/record.url?scp=85121605623&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ea141c19-57b7-36fa-9ddf-c7af082f0ad7/
U2 - 10.1002/ajmg.a.62613
DO - 10.1002/ajmg.a.62613
M3 - Review article
C2 - 34939736
SN - 1552-4825
VL - 188
SP - 1263
EP - 1279
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 4
ER -